Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-13
2008-09-16
Solola, Taofiq A (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S491000
Reexamination Certificate
active
07425550
ABSTRACT:
A compound of formula I is provided having the structurewhereinW is as defined herein;X is —CHR5O—;Y is a bond;Z is an aryl or heteroaryl group; andR1, and R2, are as described herein.Further provided is a method for treating diabetes and related diseases employing the above compound, either alone or in combination with another therapeutic agent.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3749715 (1973-07-01), Stein et al.
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4512988 (1985-04-01), Weller, III et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4692522 (1987-09-01), Parsons et al.
patent: 4755509 (1988-07-01), Teulon
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5206235 (1993-04-01), Fisher et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5545735 (1996-08-01), Bochis et al.
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5594006 (1997-01-01), Sakamoto et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Watterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5652363 (1997-07-01), Khanna et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5719278 (1998-02-01), Albright et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5789587 (1998-08-01), Fisher et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5849918 (1998-12-01), Esser et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5952322 (1999-09-01), Hoover et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6017926 (2000-01-01), Askew et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 0142146 (1985-05-01), None
patent: 0160546 (1985-11-01), None
patent: 0107095 (1987-09-01), None
patent: 0416740 (1991-03-01), None
patent: 0978279 (2000-02-01), None
patent: 1088824 (2001-04-01), None
patent: 1177791 (2002-02-01), None
patent: 2596363 (1987-10-01), None
patent: 2205837 (1988-12-01), None
patent: 8-259447 (1996-10-01), None
patent: 2000-256318 (2000-09-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 93/14067 (1993-07-01), None
patent: WO 97/21993 (1993-09-01), None
patent: WO 96/36596 (1996-11-01), None
patent: WO 96/38144 (1996-12-01), None
patent: WO 96/39384 (1996-12-01), None
patent: WO 96/39385 (1996-12-01), None
patent: WO 97/12613 (1997-04-01), None
patent: WO 97/12615 (1997-04-01), None
patent: WO 97/43268 (1997-11-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 99/26659 (1999-06-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/43663 (1999-09-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/67278 (1999-12-01), None
patent: WO 99/67279 (1999-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/47206 (2000-08-01), None
patent: WO 00/59506 (2000-10-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 01/21602 (2001-03-01), None
patent: WO 01/27128 (2001-04-01), None
Albright, J.D. et al., “Synthesis of 1,4,5,6-Tetrahydropyrazolo[3,4-d]pyrido[3,2-b]azepine”, J. Heterocyclic Chem., vol. 37, pp. 41-46 (2000).
Aranyos, A. et al., “Novel Electron-Rich Phosphine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers”, J. Am. Chem. Soc., vol. 121, pp. 4369-4378 (1999).
Arbeeny, C. et al., “The Metabolic Syndrome: From Pathophysiology to Novel Treatment Strategies”, Curr. Med. Chem.—Imm., Endoc. & Metab. Agents, vol. 1, No. 1, pp. 1-24 (2001).
Armstrong, III, J.D. et al., “An Efficient Asymmetric Synthesis of (R)-3-Amino-2,3,4,5-tetrahydro-1H-[1]benzazepin-2-one”, Tetrahedron Letters, vol. 35, No. 20, pp. 3239-3242 (1994).
Ashworth, D.M. et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ball, J.B. et al., Syntheses and Conformational Analyses of Some 3-Amino-2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepine Derivatives, etc., J. Heterocyclic Chem., vol. 27, pp. 279-286 (1990).
Bell, I.M. et al., “Development of Orally Active Oxytocin Antagonists, etc.”, J. Med. Chem., vol. 41, No. 12, pp. 2146-2163 (1998).
Berg-Nielsen, K. et al., “Amino-Claisen Rearrangement of Vinyl Propargylamines and Pryindane Synthesis from a Divinyl Ketone”, Acta Chemica Scandinavica B, vol. 32, pp. 553-556 (1978).
Biller, S.A. et al., “Isoprenoid (Phosphinylmethyl)phosphonates as Inhibitors of Squalene Synthetase”, Journal of Medicinal Chemistry, vol. 31, No. 10, pp. 1869-1871 (1988).
Biller, S.A. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, No. 1, pp. 1-40 (1996).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Caprathe, B.W. et al., “Dopamine Autoreceptor Agonists as Potential Antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine”, J. Med. Chem., vol. 34, pp. 2736-2746 (1991).
Capson, T.L., “Synthesis and Evaluation of Ammonium Analogs of Carbocationic Intermediates in Squalene Biosynthesis”, dissertation, Department of Medicinal Chemistry, University of Utah, pp. iv-v, table of contents, 16-17, 40-43, 48-51, Summary (Jun. 1987).
Carling, R.W. et al., “3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory Acid Antagonists Acting at Glycine-Site NMDA, etc.”, J. Med. Chem., vol. 36, No. 22, pp. 3397-3408 (1993).
Casimir, J.R. et al., “Efficient Synthesis of (S)-4-Phthalimido-1,3,4,5- tetrahydro-8-(2,6-dichlorobenzyloxy)-3-oxo-2-benzazepin-2-acetic Acid (Pht-Hba(2,6-Cl2-Bn)-Gly-OH)”, J. Org. Chem., vol. 65, pp. 6487-6492 (2000).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration That ‘Presqualene Pyrophosphate’ Is an Essential Intermediate on the Path to Squalene”, J. Am. Chem. Soc., vol. 98, No. 5, pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmacteuical Design, vol. 5, No. 1, pp. 11-20 (1999).
Davis, A.L. et al., “Preparation and Antimicrobial Properties of the D and L Forms of 3-Amino-3,4-dihydro-1-hydroxycarbostyril”, Journal of Medicinal Chemistry, vol. 15, No. 3, pp. 325-327 (1972).
Davis, A.L. et al., “Synthesis of the 3-Methyl and 4-Methyl Derivatives of 3-Amino-3,4-dihydro-1-hydroxycarbostyril and Related Compounds”, J. Heterocyclic Chem., vol. 17, pp. 1405-1408 (1980).
Davis, A.L. et al., “The Syntheses and Biological Activities of o-Aminophenylalanine and Related Compounds”, Archives of Biochemistry and Biophysics, vol. 102, pp. 48-51 (1963).
DeVita, R.J. et al., ȁ
Ellsworth Bruce
Sher Philip
Stouch Terry
Wu Gang
Bristol-Meyers Squibb Company
Rodney Burton
Solola Taofiq A
LandOfFree
Lactam glycogen phosphorylase inhibitors and method of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lactam glycogen phosphorylase inhibitors and method of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactam glycogen phosphorylase inhibitors and method of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981829